◼ Archived
Business
🔮 Archynetys predicts: fades by tomorrow — graded ✓ correct
AbbVie to Buy Immunology Drugmaker Apogee for $10.9 Billion
5sources
5articles
3velocity
+0%since first seen
20d agofirst detected
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
Coverage (5)
- 3 Biotech Takeover Targets Wall Street Is Watching After the Apogee Deal Yahoo Finance · 20d ago
- Why AbbVie Is Spending $11 Billion to Buy Apogee Therapeutics—and Why the Stock Is Rising Barron's · 20d ago
- AbbVie Goes On The Offensive With $10.9 Billion Takeover Investor's Business Daily · 20d ago
- AbbVie to buy Waltham’s Apogee Therapeutics in nearly $11 billion deal The Boston Globe · 20d ago
- AbbVie sharpens immunology focus with $10.9 billion Apogee deal Reuters · 20d ago
Related trends
▲ Peaking
Business
🔮 fades
Campaign text messages could soon get more effective
AI's role in U.S. election campaigns is expanding, with text messages becoming more effective.
▲ Peaking
Business
🔮 fades
Japan’s top pension fund likely to brush off political pressure
Japan's top pension fund faces political pressure to invest more domestically, but may resist.
▲ Peaking
Business
🔮 fades
CBS’ Matt Gutman Said He Got “Completely Scammed” By Fake Bank Fraud Investigator: “Scary Experience”
CBS News correspondent Matt Gutman reveals a close call with a sophisticated bank scam
▲ Peaking
Business
🔮 fades
2 Retirement Income Powerhouses For Inflationary Times
Investors are seeking strategies to protect retirement savings from inflation.
▲ Peaking
Business
🔮 fades
Scottsdale Circle K manager fights for lottery prize
▲ Peaking
Business
🔮 fades
US cybersecurity agency CISA had to build its incident playbook during the incident, agency reveals
The US Cybersecurity and Infrastructure Security Agency (CISA) is under scrutiny after revealing it had to create its incident response plan mid-crisis.